PA
MDGL icon

Parallel Advisors’s Madrigal Pharmaceuticals MDGL Stock Holding History

Parallel Advisors’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$142K Buy
264
+6
+2% +$3.07K ﹤0.01% 1490
2026
Q1 		$135K Buy
258
+7
+3% +$3.34K ﹤0.01% 1403
2025
Q4 		$146K Sell
251
-8
-3% -$4.09K ﹤0.01% 1252
2025
Q3 		$119K Sell
259
-13
-5% -$4.85K ﹤0.01% 1333
2025
Q2 		$82.3K Sell
272
-12
-4% -$3.58K ﹤0.01% 1454
2025
Q1 		$94.1K Buy
284
+85
+43% +$27.9K ﹤0.01% 1304
2024
Q4 		$61.4K Buy
199
+111
+126% +$31.2K ﹤0.01% 1515
2024
Q3 		$18.7K Hold
88
– – ﹤0.01% 2137
2024
Q2 		$24.7K Buy
88
+5
+6% +$1.19K ﹤0.01% 1864
2024
Q1 		$22.2K Hold
83
– – ﹤0.01% 1921
2023
Q4 		$19.2K Buy
83
+78
+1,560% +$13.6K ﹤0.01% 1970
2023
Q3 		$730 Hold
5
– – ﹤0.01% 3032
2023
Q2 		$1.16K Hold
5
– – ﹤0.01% 2892
2023
Q1 		$1.21K Hold
5
– – ﹤0.01% 2912
2022
Q4 		$1.45K Buy
+5
New +$489 ﹤0.01% 2798
2022
Q2 		– Sell
-3
Closed – – 3209
2022
Q1 		$0 Buy
+3
New +$253 ﹤0.01% 3147
2021
Q3 		– Sell
-2
Closed – – 3191
2021
Q2 		$0 Buy
+2
New +$237 ﹤0.01% 3007

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Parallel Advisors's MDGL Position: Q2 2026 in Review

Parallel Advisors increased its Madrigal Pharmaceuticals (MDGL) stake by 2.3% in Q2 2026, buying an estimated $3.07K and bringing the position to 264 shares worth $142K. The position accounts for ﹤0.01% of the portfolio, ranked #1490.

Parallel Advisors first reported a position in MDGL in Q2 2021 and has held it in 17 quarters since. The position peaked at $146K in Q4 2025. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Parallel Advisors held 264 shares of Madrigal Pharmaceuticals worth $142K as of Q2 2026.
  • Parallel Advisors bought 6 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $3.07K.
  • Madrigal Pharmaceuticals made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #1490 holding.
  • Parallel Advisors first reported a position in Madrigal Pharmaceuticals in Q2 2021 and has held it in 17 quarters since.
  • Parallel Advisors's Madrigal Pharmaceuticals position peaked at $146K in Q4 2025.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.